When it comes to finding new treatments for cancer scientitists have been focusing on an anti-cancer agent known as Small interfering ribonucleic acid (siRNA). But getting this agent to cancer cells has been a challenge.
Scientists have developed a platform using nanoparticles to send a cancer-fighting agent to cells.
On its surface, the plan was simple: gene-hack mosquitoes so their offspring immediately die, mix them with disease-spreading bugs in the wild, and watch the population drop off. Unfortunately, that didn’t quite pan out.
The genetically-altered mosquitoes did mix with the wild population, and for a brief period the number of mosquitoes in Jacobino, Brazil did plummet, according to research published in Nature Scientific Reports last week. But 18 months later the population bounced right back up, New Atlas reports — and even worse, the new genetic hybrids may be even more resilient to future attempts to quell their numbers.
Transplanted brain stem cells survive without anti-rejection drugs in mice. By exploiting a feature of the immune system, researchers open the door for stem cell transplants to repair the brain.
In experiments in mice, Johns Hopkins Medicine researchers say they have developed a way to successfully transplant certain protective brain cells without the need for lifelong anti-rejection drugs.
A report on the research, published today (September 16, 2019) in the journal Brain, details the new approach, which selectively circumvents the immune response against foreign cells, allowing transplanted cells to survive, thrive and protect brain tissue long after stopping immune-suppressing drugs.
Age is not the definitive factor it’s made out to be when it comes to our health. We can use our age as a baseline for tracking our health and longevity, but it isn’t stagnant. For example, certain types of testing can help us compare our biological age to our calendar age in order to tinker with our wellness routine and achieve the milestones we’re after. With the right steps, we can slow down and even sometimes reverse the aging process.
When it comes to our biological age, or the measure of how well our body is actually functioning for whatever life stage we are in, there are many things that impact it. Diet, lifestyle patterns like exercise and sleep, and stress are all involved in forming our biological age, along with many other factors like blood sugar, inflammation, and genetics. This week on The Doctor’s Farmacy, I’m joined by Dr. David Sinclair to explore the topic of longevity and anti-aging and how he reduced his own internal age by more than 20 years. Dr. Sinclair is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, where he and his colleagues study longevity, aging, and how to slow its effects.
This episode of The Doctor’s Farmacy is brought to you by ButcherBox. Now through September 29, 2019, new subscribers to ButcherBox will receive ground beef for life. When you sign up today, ButcherBox will send you 2lbs of 100% pasture-raised grass-fed, grass finished beef free in every box for the life of your subscription. Plus listeners will get an additional $20 off their first box. All you have to do is head over to ButcherBox.com/farmacy
_____________________________________
Dr. Hyman is an 11-time New York Times bestselling author, family physician and international leader in the field of Functional Medicine. His podcast, The Doctor’s Farmacy, is a place for deep conversations about the critical issues of our time in the space of health, wellness, food and politics. New episodes are released every Wednesday here on YouTube, and wherever you listen to podcasts.
Find him and more of his content all over social media:
Website http://www.drhyman.com/
Scientists from the University of Cambridge have developed a platform that uses nanoparticles known as metal-organic frameworks to deliver a promising anti-cancer agent to cells.
Research led by Dr. David Fairen-Jimenez, from the Cambridge Department of Chemical Engineering and Biotechnology, indicates metal-organic frameworks (MOFs) could present a viable platform for delivering a potent anti-cancer agent, known as siRNA, to cells.
Small interfering ribonucleic acid (siRNA), has the potential to inhibit overexpressed cancer-causing genes, and has become an increasing focus for scientists on the hunt for new cancer treatments.
Medications that mitigate inflammation caused by a variety of diseases including rheumatic arthritis may also compromise a person’s immune system, but a new approach points to a possible solution to this problem.
Researchers have discovered a mechanism that might alleviate inflammation by suppressing the migration of a type of white blood cells called neutrophils. The cells migrate within tissues in order to kill pathogens but may also cause excessive inflammation, resulting in tissue injury and other adverse effects.
The scientists identified a genetic molecule called miR-199, a type of “microRNA,” which reduces the migration of neutrophils, therefore potentially relieving inflammation without compromising the immune system.
Scientists show the approach can kill cells that cause hardening of heart tissue in mice.
Ira Pastor, ideaXme longevity and aging ambassador and Founder of Bioquark, interviews Robin Farmanfarmaian, medical futurist, bestselling author, professional speaker, and CEO and Co-Founder of ArO.
Ira Pastor Comments:
In 2019, we are spending over $7 trillion around the globe on healthcare. $1 trillion goes to pharmaceutical products, $350 billion to medical devices, $200 billion new life sciences R&D, and on and on.
We tend to forget how much consolidation has occurred in these different healthcare segments. The world’s 10 largest pharmaceutical companies control 60% of that trillion dollar market. The top 8 insurance companies in the U.S. control over 50% of all individual patient coverage. In 43 countries, which account for 3/4 the world’s population, patients only have appointment times between 5- 10 minutes with their primary care physicians. As patients, we know what it’s like to feel somewhat separated and insignificant in this system.
We usually talk on this show about the future, and the amazing technologies and products coming down the pipeline for more dramatic things, such as complex regeneration, disease reversion, radical life extension and so forth, but it’s equally important to speak on how we as individuals and patients can put ourselves back in the driver’s seat and not just be an afterthought in the equation.
Today’s guest, who knows a lot about this topic, is Ms. Robin Farmanfarmaian. Robin is a medical futurist, entrepreneur, bestselling author, and professional speaker. She focuses on the future of integrated medicine, the changing role of patients in healthcare decision-making, and how technology will change the way we experience and interact with medical facilities and physicians.
In experiments in mice, Johns Hopkins Medicine researchers say they have developed a way to successfully transplant certain protective brain cells without the need for lifelong anti-rejection drugs.
A report on the research, published Sept. 16 in the journal Brain, details the new approach, which selectively circumvents the immune response against foreign cells, allowing transplanted cells to survive, thrive and protect brain tissue long after stopping immune-suppressing drugs.
The ability to successfully transplant healthy cells into the brain without the need for conventional anti-rejection drugs could advance the search for therapies that help children born with a rare but devastating class of genetic diseases in which myelin, the protective coating around neurons that helps them send messages, does not form normally. Approximately 1 of every 100,000 children born in the U.S. will have one of these diseases, such as Pelizaeus-Merzbacher disease. This disorder is characterized by infants missing developmental milestones such as sitting and walking, having involuntary muscle spasms, and potentially experiencing partial paralysis of the arms and legs, all caused by a genetic mutation in the genes that form myelin.
